Seretide and
Symbicort in asthma management
Relevant BNF section: 3.2
Maintenance treatment for mild asthma frequently comprises both a regular inhaled corticosteroid and an 'as required' inhaled short-acting ß2-agonist. Where such treatment fails, additional regular treatment with an inhaled long-acting ß2-agonist is increasingly recommended.1 In the UK, combination inhalers containing salmeterol + fluticasone (
Seretide - Allen & Hanburys) or formoterol + budesonide (
Symbicort - AstraZeneca) are licensed for use either in "patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting ß2-agonists" or in "patients already adequately controlled on both inhaled corticosteroids and long-acting -agonists".2–4 Here we review the efficacy of Seretide and Symbicort and discuss their place in asthma management.
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
